Biovail Presents Three Poster Presentations at the American Society of Hypertension.Business Editors/Health/Medical Writers TORONTO--(BUSINESS WIRE)--May 14, 2003 Biovail Corporation (NYSE NYSE See: New York Stock Exchange :BVF BVF Biovail Corporation (stock symbol) BVF Berufsverband der Frauenärzte eV (Muenchen, Germany) BVF Bearing Versus Frequency )(TSX TSX Toronto Stock Exchange (TSE before April, 2002) TSX Transfer from Stack Pointer to Index TSX True Space Extension :BVF) announced today that the results from three clinical programs will be given as poster presentations at the American Society of Hypertension Conference to be held at the Marriott Marquis Hotel, in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. . The posters will remain available for the entire day. The formal presentation schedule is as follows: "Comparison of nocturnal dosing of diltiazem extended release (ER) and ramipril on early morning blood pressure, heart rate and the rate-pressure product" Friday May 16, 2003 3:30 - 5:00 pm "Efficacy of nighttime dosing of graded-release diltiazem versus morning dosing of amlodipine in African American patients with stages I and II essential hypertension" Friday May 16, 2003 3:30 - 5:00 pm "A 13-week, double-blind, placebo-controlled, parallel, multi-center study of eprosartan mesylate given in titrated ti·trate tr. & intr.v. ti·trat·ed, ti·trat·ing, ti·trates To determine the concentration of (a solution) by titration or perform the operation of titration. doses of 600mg or 1200mg once daily in patients with isolated systolic hypertension." Friday May 16, 2003 3:30 - 5:00 pm These posters will be posted to the Biovail web site (www.biovail.com) following the formal presentations. Biovail Corporation is an international full-service pharmaceutical company, engaged in the formulation, clinical testing, registration, manufacture, sale and promotion of pharmaceutical products utilizing advanced drug delivery technologies. For further information, please contact Ken Howling at 905-286-3000 or send inquiries to ir@biovail.com. "Safe Harbor" statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. To the extent any statements made in this release contain information that is not historical, these statements are essentially forward looking and are subject to risks and uncertainties, including the difficulty of predicting FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, the regulatory environment, fluctuations in operating results and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion